QBIO - Q BioMed chemotherapy Uttroside B for liver cancer to get US patent

• Q BioMed ( OTCQB:QBIO ) said its chemotherapeutic Uttroside B is expected to receive a patent in the U.S linked to liver cancer
• The company noted that it received a notice of allowance from the U.S. Patent Office for the patent titled 'Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma (HCC).'
• Q BioMed said it has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology in India, and the Oklahoma Medical Research Foundation.
• The company added that results from pre-clinical pharmacokinetic testing have been encouraging and the data supports advancing the program.

For further details see: